55 related articles for article (PubMed ID: 33416143)
21. A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders.
Zhang L; Luo L; Chen JY; Singh R; Baldwin WM; Fox DA; Lindner DJ; Martin DF; Caspi RR; Lin F
JCI Insight; 2023 Dec; 8(23):. PubMed ID: 37917882
[TBL] [Abstract][Full Text] [Related]
22. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity.
Zhu XY; Li QX; Kong Y; Huang KK; Wang G; Wang YJ; Lu J; Hua GQ; Wu YL; Ying TL
Acta Pharmacol Sin; 2024 Mar; 45(3):609-618. PubMed ID: 38030799
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.
Schreiber AR; Nguyen A; Bagby SM; Arcaroli JJ; Yacob BW; Quackenbush K; Guy JL; Crowell T; Stringer B; Danaee H; Kalebic T; Messersmith WA; Pitts TM
Clin Cancer Drugs; 2018; 5(1):42-49. PubMed ID: 30631747
[TBL] [Abstract][Full Text] [Related]
24. EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors.
Capone E; Lattanzio R; Gasparri F; Orsini P; Rossi C; Iacobelli V; De Laurenzi V; Natali PG; Valsasina B; Iacobelli S; Sala G
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33918158
[TBL] [Abstract][Full Text] [Related]
25. Aptamer-Driven Toxin Gene Delivery in U87 Model Glioblastoma Cells.
di Leandro L; Giansanti F; Mei S; Ponziani S; Colasante M; Ardini M; Angelucci F; Pitari G; d'Angelo M; Cimini A; Fabbrini MS; Ippoliti R
Front Pharmacol; 2021; 12():588306. PubMed ID: 33935695
[TBL] [Abstract][Full Text] [Related]
26. Antibody Glycoengineering and Homogeneous Antibody-Drug Conjugate Preparation.
Manabe S; Yamaguchi Y
Chem Rec; 2021 Nov; 21(11):3005-3014. PubMed ID: 33886147
[TBL] [Abstract][Full Text] [Related]
27. AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X
Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522
[TBL] [Abstract][Full Text] [Related]
28. HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target.
Capone E; Tryggvason T; Cela I; Dufrusine B; Pinti M; Del Pizzo F; Gunnarsdottir HS; Grottola T; De Laurenzi V; Iacobelli S; Lattanzio R; Sala G
Cell Death Discov; 2023 Oct; 9(1):400. PubMed ID: 37898642
[TBL] [Abstract][Full Text] [Related]
29. HER3 in cancer: from the bench to the bedside.
Gandullo-Sánchez L; Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2022 Oct; 41(1):310. PubMed ID: 36271429
[TBL] [Abstract][Full Text] [Related]
30. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
Aschmoneit N; Kühl L; Seifert O; Kontermann RE
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
[TBL] [Abstract][Full Text] [Related]
31. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
Aschmoneit N; Steinlein S; Kühl L; Seifert O; Kontermann RE
Sci Rep; 2021 Jul; 11(1):13880. PubMed ID: 34230555
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
33. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
[TBL] [Abstract][Full Text] [Related]
34. [Design of next generation antibody drug conjugates].
Zhu GD; Fu YX
Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
[TBL] [Abstract][Full Text] [Related]
35. Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs.
Singh SB
J Nat Prod; 2022 Mar; 85(3):666-687. PubMed ID: 35072477
[TBL] [Abstract][Full Text] [Related]
36. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
[TBL] [Abstract][Full Text] [Related]
37. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.
Capone E; Lamolinara A; D'Agostino D; Rossi C; De Laurenzi V; Iezzi M; Iacobelli S; Sala G
J Control Release; 2018 May; 277():48-56. PubMed ID: 29550398
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
